Collectively, we have defined ENT2-mediated adenosine signaling in V1 as the neurochemical basis for 40 Hz flickering-induced sleep, and developed a novel and non-invasive treatment for insomnia with potentially wider therapeutic implications. Here, SLC29A2 is linked to insomnia measurement.